Results 211 to 220 of about 7,205 (295)

Efficient variant phasing utilizing a replication cycle reaction system. [PDF]

open access: yesGenet Med Open
Mitsutake A   +5 more
europepmc   +1 more source

Nature of Surface Microcracks on Phosphorus Micro‐Alloyed Copper

open access: yesMaterials and Corrosion, EarlyView.
SSRT tests and microscopic characterization methods were used to study the effect of plastic deformation and environment on the formation of surface microcracks on Cu‐OFP. Results show that, while ambient conditions produced thousands of microcracks per mm2, exposure to sulfide water resulted in fewer microcracks with no evidence of crack growth ...
Ahsan Chonche   +4 more
wiley   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri   +20 more
wiley   +1 more source

Continuous Apomorphine Infusion in Multiple System Atrophy Real‐World Insights From a French Nationwide Retrospective Cohort

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy   +16 more
wiley   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau   +3 more
wiley   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor   +2 more
wiley   +1 more source

Whole-genome sequence of an extensively drug-resistant <i>Acinetobacter baumannii</i> strain, AB/Mali-Bko/NPHI-APR.10, isolated from Bamako, Mali, in 2025. [PDF]

open access: yesMicrobiol Resour Announc
Dicko CH   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy